Skip to main content

What type of drug is Copiktra?

Medically reviewed by Judith Stewart, BPharm. Last updated on May 8, 2025.

Official Answer by Drugs.com

Copiktra (duvelisib) is an oral inhibitor of phosphoinositide 3-kinase (PI3K), and the first approved dual inhibitor of PI3K-delta and PI3K-gamma, two enzymes known to help support the growth and survival of malignant B-cells (cancerous white blood cells).

Copiktra is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies, when they did not work or are no longer working.

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are both cancers that affect lymphocytes, a type of white blood cell that plays an important role in the immune system.

CLL and SLL are essentially the same disease, with the only difference being the location where the cancer primarily occurs.

Copiktra also initially received accelerated approval for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The approval for FL was based on overall response rate, with continued approval contingent upon verification of clinical benefit in confirmatory trials.

Secura Bio, Inc. announced the voluntarily withdrawal of follicular lymphoma indication for Copiktra in December 2021.

Read next

How will I feel after a Rituxan infusion?

After a Rituxan (rituximab) infusion you may experience certain side effects or adverse reactions that make you feel unwell. Common side effects include nausea, infusion-related reactions, and feeling tired. Continue reading

How long does it take for Rituxan to work?

Patients treated with Rituxan may notice an early response within 7-8 weeks of treatment. Most rheumatoid arthritis patients will notice some improvement in their symptoms, such as improvement in their levels of pain and inflammation, within 16 weeks of starting treatment with Rituxan. Continue reading

How does the drug Rituxan work?

Rituxan (rituximab) is a monoclonal antibody that targets the CD20 protein found on the surface of B-cells, a type of white blood cell involved in immune responses. By binding to CD20, Rituxan helps eliminate these cells, which is beneficial in treating certain cancers and autoimmune disorders. Continue reading

See also:

Related medical questions

Drug information

Related support groups